Evaluating The Efficacy Of Combined Cognitive Processing Therapy and Stellate Ganglion Blocks for PTSD

ConditionPTSD
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorRush University Medical Center

About this trial

The purpose of this study is to understand if we can improve the treatment for posttraumatic stress disorder (PTSD). We are looking into whether the combination of Stellate Ganglion Block (SGB) treatment and Cognitive Processing Therapy (CPT) can reduce symptoms of PTSD. CPT is a trauma-focused talk therapy that can help identify and challenge unhelpful trauma-related beliefs about oneself, others, and the world. It is known to be a highly effective talk therapy for PTSD. SGB treatment is a procedure involving an injection of local anesthetic into a bundle of nerves located in the neck that is part of the sympathetic nervous system which controls our body's response to stressful situations and blocks pain.

The proposed project will systematically test whether combining CPT with SGB produces greater PTSD symptom reductions and functional improvements in the short- and longer-term up to 6-months follow-up compared to CPT (+Placebo) or SGB (+Daily Monitoring) alone.

Eligibility criteria

Qualifiers

Are 18 years or older

Are fluent in English

Have experienced a Criterion A traumatic event during their lifetime

Have a PTSD diagnosis verified via the Clinician Administered PTSD Scale for DSM-5

Disqualifiers

The traumatic event occurred in the past month

They are currently suicidal or homicidal (i.e., plan and intent)

They have unmanaged psychosis or mania

They have not been on a stable dose of psychotropic medication for at least one month by the time of the baseline assessment or are planning to change their medications within 3 months of starting their participation in the study

Trial design

Treatments tested in this trial

  • Cognitive Processing Therapy
  • Stellate Ganglion Block

Treatment groups

270 Participants
are divided into 3 treatment groups

Locations

1
Rush University Medical Center60612, ChicagoIllinois, United States

Sponsors and collaborators

Rush University Medical Center

Lead sponsor